Laura Girardi on Anticoagulant Treatment for Isolated Distal DVT: Finally Our Official Paper Is Out!
Laura Girardi, Clinical and Research Thrombosis Fellow at The Ottawa Hospital, shared on LinkedIn:
”Finally our official paper is out!
An updated systematic review with meta-analysis on management of isolated distal DVT (IDDVT).
Thanks to my fabulous colleagues to have made it possible.
Efficacy outcomes (recurrent DVT, PE, proximal progression of IDDVT and PTS) and safety outcomes (major bleeding and CRNMB) are mainly presented depending on different approaches:
1. No anticoagulation
2. Short duration of anticoagulation (<6 weeks)
3. Long duration (6-12 weeks)
4. Extended-anticoagulation (>12 weeks)
- Patients receiving short courses of anticoagulation had higher risk of recurrent VTE (RR=2.72; 95% CI: 1.19-6.23) and proximal progression (RR=3.86; 95% CI: 1.77-8.43) than patients receiving long anticoagulation, with similar bleeding risk in patients with IDDVT.
- Anticoagulation seemed associated with lower risk of recurrent VTE and proximal progression, and similar bleeding risk compared to no anticoagulant treatment.
- The incidence of PTS was 30% in untreated patients, 11% in short, and 0% in long anticoagulation.
- Long-term treatment duration appeared to be more effective.
Please find more details (e.g. dose and type of anticoagulation, baseline patients’ risks, etc.) in the full text!”
Read the full article in Haematologica.
Article: Anticoagulant treatment for isolated distal deep vein thrombosis: a systematic review and meta-analysis
Authors: Matteo Guarascio, Emanuele Valeriani, Laura Girardi, Matteo Candeloro, Arianna Pannunzio, Ilaria Maria Palumbo, Marcello Di Nisio, Walter Ageno

Stay updated on all scientific advances in the field of thrombosis with Hemostasis Today.
-
Sep 8, 2026, 16:14Heghine Khachatryan: Colombo 2026 Insights on Point-of-Care Ultrasound in Hemophilia Joint Care
-
Sep 8, 2026, 15:57Flora Peyvandi: Efficiency Meets Innovation in Hemophilia B Gene Therapy
-
Sep 8, 2026, 15:48Maxime Dely: Guillain-Barré Syndrome – What if the Key Lies in the Plasma?
-
Sep 8, 2026, 15:34Ron DePinho: A Negative Trial Highlights the Need for Precision in Cardiovascular Inflammation
-
Sep 8, 2026, 15:31Adil Yousaf: Thrombolysis Speed Matters, but Eligibility Comes First
-
Sep 8, 2026, 15:28Dhargam Aljebouri: First Molecularly Characterized Para-Bombay Phenotype in the Arab World
-
Sep 8, 2026, 15:27Mohd Ashhad: How Much Does Hemoglobin Increase After 1 Unit of PRBC?
-
Sep 8, 2026, 15:27Sanish Babu: The Hematocrit–Platelet Signal in Severe Dengue
-
Sep 8, 2026, 15:26Mary Kama: Climate-Informed Early Warning Systems for Sickle Cell Anaemia